RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 PIONEER II: Adalimumab Reduces Disease Activity in Patients with HS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 37
SP 10
OP 11
DO 10.1177/155989771437006
UL http://mdc.sagepub.com/content/14/37/10.abstract
AB Hidradenitis suppurativa (HS) is a chronic, painful skin disease for which there is currently no approved treatment. Results from the Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa [PIONEER II; NCT01468233] show that patients with moderate-to-severe HS who are treated with adalimumab experience a clinically relevant reduction in objective disease activity and pain after 12 weeks, as discussed in this article.